Anixa Biosciences’ (ANIX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report report published on Tuesday,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the stock.

A number of other analysts have also commented on ANIX. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Monday, March 23rd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Anixa Biosciences presently has a consensus rating of “Hold” and an average target price of $8.50.

Anixa Biosciences Stock Performance

ANIX stock opened at $2.55 on Tuesday. The stock’s 50 day simple moving average is $2.87 and its 200 day simple moving average is $3.51. The company has a market cap of $85.50 million, a P/E ratio of -7.73 and a beta of 0.57. Anixa Biosciences has a fifty-two week low of $2.33 and a fifty-two week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Equities analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Buying and Selling at Anixa Biosciences

In related news, Director Arnold M. Baskies bought 10,000 shares of the company’s stock in a transaction dated Wednesday, January 28th. The shares were bought at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the acquisition, the director directly owned 135,000 shares of the company’s stock, valued at $410,400. This trade represents a 8.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 26.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. NewEdge Advisors LLC bought a new position in shares of Anixa Biosciences during the 2nd quarter worth approximately $33,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Anixa Biosciences by 2,000.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after acquiring an additional 10,000 shares during the last quarter. Cetera Investment Advisers purchased a new stake in shares of Anixa Biosciences during the fourth quarter valued at approximately $35,000. Benjamin Edwards Inc. bought a new stake in Anixa Biosciences during the second quarter worth $37,000. Finally, Marshall Wace LLP bought a new position in Anixa Biosciences in the 2nd quarter valued at $39,000. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.